Heart Failure Reviews

, Volume 19, Issue 4, pp 541–551 | Cite as

Prediction of clinical outcomes using B-type natriuretic peptides in the general population: a systematic review

  • Andrew C. Don-Wauchope
  • Pasqualina L. Santaguida
  • Robert McKelvie
  • Judy A. Brown
  • Mark Oremus
  • Usman Ali
  • Amy Bustamam
  • Nazmul Sohel
  • Stephen A. Hill
  • Ronald A. Booth
  • Cynthia Balion
  • Parminder Raina
Article

Abstract

The use of B-type natriuretic peptides to predict outcomes in general populations has been investigated in a number of primary studies. A previous systematic review considering natriuretic peptides in cardiovascular disease included a subgroup of general population studies, which suggested an association with a number of clinical outcomes. We electronically searched Medline, Embase, AMED, Cochrane Central Register of Controlled Trials, Cochrane Database of Systematic Reviews, and CINAHL for English-language articles published between 1989 and mid-2012. We utilized trained reviewers and standardized forms to screen articles for inclusion and extract data from included articles. All included studies (n = 7) were summarized in narrative and tabular form. A general population was defined as one that was randomly selected from a community setting where no specific inclusion or exclusion criteria were specified. The seven included studies all used FDA approved assays for NT-proBNP. The range of clinical outcomes and heterogeneity did not allow for meta-analysis. The hazard ratios for predicting outcomes in the included studies ranged from 1.0 to 4.1 (all p values <0.05). The discrimination statistics reported in four studies all demonstrated statistically significant improvements in predicting outcomes. NT-proBNP is associated with heart failure, all-cause and cardiovascular mortality, and other combined cardiovascular events in a general unselected population. The discrimination statistics suggest modest improvements in risk stratification. No prospective studies exist to demonstrate the clinical utility of using B-type natriuretic peptides to predict clinical outcomes in a general population.

Keywords

Natriuretic peptide General population Prognosis Discrimination statistics Systematic review 

References

  1. 1.
    Greenland P, Alpert JS, Beller GA, Benjamin EJ, Budoff MJ, Fayad ZA et al (2010) 2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults. J Am Coll Cardiol 56:e50–e103. doi:10.1016/j.jacc.2010.09.001 PubMedCrossRefGoogle Scholar
  2. 2.
    Daniels LB, Laughlin GA, Clopton P, Maisel AS, Barrett-Connor E (2008) Minimally elevated cardiac troponin T and elevated N-terminal pro-B-type natriuretic peptide predict mortality in older adults: results from the Rancho Bernardo Study. J Am Coll Cardiol 52:450–459. doi:10.1016/j.jacc.2008.04.033 PubMedCentralPubMedCrossRefGoogle Scholar
  3. 3.
    Zethelius B, Berglund L, Sundström J, Ingelsson E, Basu S, Larsson A et al (2008) Use of multiple biomarkers to improve the prediction of death from cardiovascular causes. N Engl J Med 358:2107–2116. doi:10.1056/NEJMoa0707064 PubMedCrossRefGoogle Scholar
  4. 4.
    Melander O, Newton-Cheh C, Almgren P, Hedblad B, Berglund G, Engstrom G et al (2009) Novel and conventional biomarkers for prediction of incident cardiovascular events in the community. JAMA 302:49–57. doi:10.1001/jama.2009.943 PubMedCentralPubMedCrossRefGoogle Scholar
  5. 5.
    Blankenberg S, Zeller T, Saarela O, Havulinna AS, Kee F, Tunstall-Pedoe H et al (2010) Contribution of 30 biomarkers to 10-year cardiovascular risk estimation in 2 population cohorts: the MONICA, risk, genetics, archiving, and monograph (MORGAM) biomarker project. Circulation 121:2388–2397. doi:10.1161/CIRCULATIONAHA.109.901413 PubMedCrossRefGoogle Scholar
  6. 6.
    Olsen MH, Hansen TW, Christensen MK, Gustafsson F, Rasmussen S, Wachtell K et al (2007) N-terminal pro-brain natriuretic peptide, but not high sensitivity C-reactive protein, improves cardiovascular risk prediction in the general population. Eur Heart J 28:1374–1381. doi:10.1093/eurheartj/ehl448 PubMedCrossRefGoogle Scholar
  7. 7.
    Di Angelantonio E, Chowdhury R, Sarwar N, Ray KK, Gobin R, Saleheen D et al (2009) B-type natriuretic peptides and cardiovascular risk: systematic review and meta-analysis of 40 prospective studies. Circ Cardiovasc Qual Outcomes 120:2177–2187. doi:10.1161/CIRCULATIONAHA.109.884866 Google Scholar
  8. 8.
    Balion C, Don-Wauchope A, Hill S, Santaguida PL, Booth R, Brown JA, Oremus M, Ali U, Bustamam A, Sohel N, McKelvie R, Raina P (2013) Use of natriuretic peptide measurement in the management of heart failure. Comparative Effectiveness Reviews, No. 126. 2013. AHRQ Publication No. 13(14)-EHC118-EF. www.effectivehealthcare.ahrq.gov/reports/final.cfm
  9. 9.
    Alehagen U, Dahlström U, Rehfeld JF, Goetze JP (2011) Association of copeptin and N-terminal proBNP concentrations with risk of cardiovascular death in older patients with symptoms of heart failure. JAMA 305:2088–2095. doi:10.1001/jama.2011.666 PubMedCrossRefGoogle Scholar
  10. 10.
    Olsen MH, Hansen TW, Christensen MK, Gustafsson F, Rasmussen S, Wachtell K et al (2008) Cardiovascular risk prediction by N-terminal pro brain natriuretic peptide and high sensitivity C-reactive protein is affected by age and sex. J Hypertens 26:26–34. doi:10.1097/HJH.0b013e3282f18301 PubMedCrossRefGoogle Scholar
  11. 11.
    Linssen GC, Bakker SJ, Voors AA, Gansevoort RT, Hillege HL, de Jong PE et al (2010) N-terminal pro-B-type natriuretic peptide is an independent predictor of cardiovascular morbidity and mortality in the general population. Eur Heart J 31:120–127. doi:10.1093/eurheartj/ehp420 PubMedCrossRefGoogle Scholar
  12. 12.
    van Hateren KJ, Alkhalaf A, Kleefstra N, Groenier KH, de Jong PE, de Zeeuw D et al (2012) Comparison of midregional pro-A-type natriuretic peptide and the N-terminal pro-B-type natriuretic peptide for predicting mortality and cardiovascular events. Clin Chem 58:293–297. doi:10.1373/clinchem.2011.166348 PubMedCrossRefGoogle Scholar
  13. 13.
    Hayden JA, Côté P, Bombardier C (2006) Evaluation of the quality of prognosis studies in systematic reviews. Ann Intern Med 144:427–437. doi:10.7326/0003-4819-144-6-200603210-00010 PubMedGoogle Scholar
  14. 14.
    Chisalita SI, Dahlström U, Arnqvist HJ, Alehagen U (2011) Increased IGF1 levels in relation to heart failure and cardiovascular mortality in an elderly population: impact of ACE inhibitors. Eur J Endocrinol 165:891–898. doi:10.1530/EJE-11-0584 PubMedCrossRefGoogle Scholar
  15. 15.
    Patton KK, Sotoodehnia N, deFilippi C, Siscovick DS, Gottdiener JS, Kronmal RA (2011) N-terminal pro-B-type natriuretic peptide is associated with sudden cardiac death risk: the Cardiovascular Health Study. Heart Rhythm 8:228–233. doi:10.1016/j.hrthm.2010.10.038 PubMedCrossRefGoogle Scholar
  16. 16.
    Smith JG, Newton-Cheh C, Almgren P, Struck J, Morgenthaler NG, Bergmann A et al (2010) Assessment of conventional cardiovascular risk factors and multiple biomarkers for the prediction of incident heart failure and atrial fibrillation. J Am Coll Cardiol 56:1712–1719. doi:10.1016/j.jacc.2010.05.049 PubMedCentralPubMedCrossRefGoogle Scholar
  17. 17.
    Vaes B, de Ruijter W, Degryse J, Westendorp RG, Gussekloo J (2009) Clinical relevance of a raised plasma N-terminal pro-brain natriuretic peptide level in a population-based cohort of nonagenarians. J Am Geriatr Soc 57:823–829. doi:10.1111/j.1532-5415.2009.02218.x PubMedCrossRefGoogle Scholar
  18. 18.
    Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH et al (2013) 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 62:e147–e239. doi:10.1016/j.jacc.2013.05.019 PubMedCrossRefGoogle Scholar
  19. 19.
    Schmitter D, Cotter G, Voors AA (2014) Clinical use of novel biomarkers in heart failure: towards personalized medicine. Heart Fail Rev 19:369–381. doi:10.1007/s10741-013-9396-5 PubMedCrossRefGoogle Scholar
  20. 20.
    Metra M, Ponikowski P, Dickstein K, McMurray JJV, Gavazzi A, Bergh C-H et al (2007) Advanced chronic heart failure: a position statement from the Study Group on Advanced Heart Failure of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 9:684–694. doi:10.1016/j.ejheart.2007.04.003 PubMedCrossRefGoogle Scholar
  21. 21.
    Arcopinto M, Bobbio E, Bossone E, Perrone-Filardi P, Napoli R, Sacca L et al (2013) The GH/IGF-1 axis in chronic heart failure. Endocr Metab Immune Disord Drug Targets 13:76–91PubMedCrossRefGoogle Scholar
  22. 22.
    Hlatky MA, Greenland P, Arnett DK, Ballantyne CM, Criqui MH, Elkind MS et al (2009) Criteria for evaluation of novel markers of cardiovascular risk: a scientific statement from the American Heart Association. Circ Cardiovasc Qual Outcomes 119:2408–2416. doi:10.1161/CIRCULATIONAHA.109.192278 Google Scholar
  23. 23.
    Payne RA (2012) Cardiovascular risk. Br J Clin Pharmacol 74:396–410. doi:10.1111/j.1365-2125.2012.04219.x PubMedCentralPubMedCrossRefGoogle Scholar
  24. 24.
    Rosenberg J, Schou M, Gustafsson F, Badskjaer J, Hildebrandt P (2009) Prognostic threshold levels of NT-proBNP testing in primary care. Eur Heart J 30:66–73. doi:10.1093/eurheartj/ehn525 PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  • Andrew C. Don-Wauchope
    • 1
  • Pasqualina L. Santaguida
    • 2
  • Robert McKelvie
    • 3
  • Judy A. Brown
    • 2
  • Mark Oremus
    • 2
  • Usman Ali
    • 2
  • Amy Bustamam
    • 2
  • Nazmul Sohel
    • 2
  • Stephen A. Hill
    • 1
  • Ronald A. Booth
    • 4
  • Cynthia Balion
    • 1
  • Parminder Raina
    • 2
  1. 1.Department of Pathology and Molecular MedicineMcMaster UniversityHamiltonCanada
  2. 2.Department of Clinical Epidemiology and BiostatisticsMcMaster UniversityHamiltonCanada
  3. 3.Department of MedicineMcMaster UniversityHamiltonCanada
  4. 4.Department of Pathology and Laboratory MedicineUniversity of OttawaOttawaCanada

Personalised recommendations